trial

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

NCTId NCT01530529
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2012-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2012-01
Primary completion
2012-04
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-05180999

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2012-04
Status
COMPLETED
relationships
The graph out of here
drug
PF-05180999
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
Healthy
indication